The European Medicines Agency has recommended the approval of Ixchiq, the first vaccine in the EU intended to protect adults against chikungunya, a viral disease transmitted by infected mosquitoes. Symptoms include fever and joint pain, with some individuals experiencing lasting joint pain or severe acute disease. The vaccine triggers the production of neutralizing antibodies and has shown a high immunogenic response in clinical studies. Additionally, the CHMP also recommended Fluenz, a live attenuated influenza vaccine for children and adolescents. Both vaccines have common side effects such as headache and fatigue. The recommendations await final approval by the European Commission.
Source link
Chikungunya Vaccine Backed by European Medicines Agency
